Active VS smouldering myeloma: Understanding disease progression

Injection Time Can Encourage Bonding During Myeloma Care

The extended injection time for subcutaneous daratumumab in those with myeloma can serve as an opportunity for oncology nurses to check in with patients.

Active VS smouldering myeloma: Understanding disease progression

New Delhi: Multiple myeloma is a cancer that arises in a white blood cell type known as a plasma cell. Normal plasma cells fight infection by producing antibodies that identify and destroy germs. It starts with a single abnormal plasma cell in the bone marrow, and the abnormal cell grows quickly. Multiple myeloma is the second most common haematological malignancy (∼15%), which is responsible for almost 20% of all haematological malignancy-relat…

The University Hospital Complex of Santiago (CHUS) will offer promising CAR-T cancer therapies to adults as well. The Ministry of Health has chosen the compostelano center and also the Chuvi de Vigo to administer this immunological treatment to adults. Less aggressive than chemotherapy, it offers a new alternative treatment for blood tumors.

CAR T in Myeloma: Anito-cel Challenges & Evolving Treatment Lines

Ciara Freeman, MD, PhD, discusses the challenges of incorporating anito-cel into the treatment protocol for patients with multiple myeloma.